Little Green Pharma : Company Update Presentation

ASX:LGP

Company Update

2 February 2022

onlyuse

ersonalOur vision is to reimagine cannabis medicines and do extraordinary things for our patients

Our purpose is to solve real patient problems

Disclaimer

Disclaimer

This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) ("LGP") and its activities current as at the date of this presentation. The information in this

onlypresentation is of general background and does not purport to be complete or to contain all the information which a prospective investor may require in evaluating a possible investment in LGP or that would be required in a prospectus or a product disclosure statement prepared in accordance with the Corporations Act 2001 (Cth) ("Corporations Act").

It should be read in conjunction with LGP's other periodic and continuous disclosure a ouncements filed with the Australian Securities Exchange, which are available at www.asx.com.au.

This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire LGP's shares or other securities. This document does not constitute or contain an offer,

useinvitation, solicitation or recommendation with respect to the purchase or sale of any security in LGP.

No liability

The information contained in this document has been prepared in good faith by LGP, however no guarantee representation or warranty expressed or implied is or will be made by any person (including LGP and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of

any statements, estimates, options, conclusions or other information contained in this ersonaldocument.

To the maximum extent permitted by law, LGP and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied,

c ntained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom.

Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice.

Not financial product advice

This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists purely of factual information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product.

An investment in LGP is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.

Forward looking statements

Certain information in this document refers to the intentions of LGP, but these are not intended to be forecasts, forward looking statements or statements about the future matters for the purposes of the Corporations Act or any other applicable law. The occurrence of the events in the future are subject to risk, uncertainties and other actions that may cause LGP's actual results, performance or achievements to differ from those referred to in this document. Accordingly, LGP and its affiliates and their directors, officers, employees and agents do not give any assurance or guarantee that the occurrence of these events referred to in the document will actually occur as contemplated. Past performance is no guarantee of future performance.

This presentation may contain forward-looking statements including statements regarding our intent, belief or current expectations with respect to LGP's business and operations, market conditions, results of operations and financial condition, specific provisions and risk management practices. When used in this presentation, the words 'likely', 'estimate', 'project', 'intend', 'forecast', 'anticipate', 'believe', 'expect', 'may', 'aim', 'should', 'potential' and similar expressions, as they relate to LGP and its management, are intended to identify forward- looking statements. Forward looking statements involve known and unknown risks, uncertainties and assumptions and other important factors that could cause the actual results, performances or achievements of LGP to be materially different from future results, performances or achievements expressed or implied by such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date thereof.

Acceptance

By accepting, accessing or reviewing this document you acknowledge and agree to the "Disclaimer" as detailed above.

2

Corporate Overview

	Capital Structure			Register Breakdown1
only	$0.545
	Current Share Price1
							Institutional
	Shares Outstanding1,2	236,211,216
							36%
	Options and Performance Rights on Issue	16,940,536
		Others
	Market Capitalisation (undiluted)1	~$128.7 million
		52%
	Cash Reserves (31 Dec 2021)	~$25.2 million					Board
	Enterprise Value3	~$103.5 million
					12%
use	Substantial Shareholders3
	Shareholder			Shareholding	Ownership
	HANCOCK PROSPECTING PTY LTD4				26.7m	11.3%
	ELIXXER LTD5				24.7m	10.5%
ersonal				20.3m	8.6%
	MS FLETA JENNIFER SOLOMON
	TIGA TRADING PTY LTD6				16.2m	6.9%
	Top 20 shareholders				130.3m	55.2%
	Board ownership				28.5m	12.1%

1. As at 1 February 2022
2. 54,034,703 shares are escrowed 24 months from date of listing (20 February 2020)
3. Calculated using net cash of $25.2m
4. Includes associated parties. Holding as advised to market on 6 July 2021
5. Holding as advised to market on 1 December 2021
6. Includes associated parties. Holding as advised to market on 2 July 2021

3

Investment Highlights

LGP is uniquely positioned to supply pharmaceutical-grade cannabis medicines across the globe

onlyMarket leader in Australian market

World class cannabis cultivation and

usemanufacturing facility

Dominant EU distribution platform

ersonalStrong product innovation and R&D pipeline

Record half yearly sales revenue of ~$6.9m (unaudited) (+84% pcp) and record cash receipts of $6.5m Record half yearly number of new prescribers (227) and new patient numbers (est. 8,500)

Estimated market share in Australia is ~20%

Two strategically located world class production facilities to service the Southern and Northern hemisphere markets

Total biomass cultivation capacity of >25 tonnes p.a.

Both facilities producing EU-GMP recognised cannabis medicines

Leading EU distribution platform with supply pathways into the UK, Germany, France, Italy, Poland, Greece and Denmark with access to over 68% of EU and UK citizens

First mover advantage in major European markets with significant capacity to meet growing demand Granted Denmark's first locally produced cannabis medicine registration with encouraging first sales

Study sponsor of the QUEST Initiative - the world's largest longitudinal clinical study investigating the quality of life and health economic impact of medicinal cannabis on patients with chronic disease

QUEST interim study findings expected mid-2022 and will guide LGP's product development pipeline Strong R&D pipeline of current market and future registered products

Continued focus on new flower medicines, with 15 additional plant genetics being developed

4

Business Model

ersonal use only